NextBioMedical Co

NextBioMedical Co Net Tangible Assets

The Net Tangible Assets of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is 48.11 B KRW. In the previous year, Net Tangible Assets was 44.85 B KRW — a change of 7.27% (higher).

Net Tangible Assets

48.11 BKRW

YoY

7.27%

Last updated:

Net Tangible Assets of NextBioMedical Co is 2025 48.11 B KRW. Net Tangible Assets of NextBioMedical Co was 2024 44.85 B KRW. It decreases by 7.27% higher compared to the previous year.

The NextBioMedical Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2021
5.08 B KRW
Jan 1, 2022
-476.03 M KRW
Jan 1, 2023
-6.12 B KRW
Jan 1, 2024
44.85 B KRW
Jan 1, 2025
48.11 B KRW
The NextBioMedical Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
48.11 BKRW+7.27%
44.85 BKRW-832.96%
-6.12 BKRW+1,185.35%
-476.03 MKRW-109.36%
5.08 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Net Tangible Assets of NextBioMedical Co is 48.11 B KRW in 2025.

Net Tangible Assets of NextBioMedical Co changed from 44.85 B KRW to 48.11 B KRW, representing a 7.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's NextBioMedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — NextBioMedical Co

All Key Metrics — NextBioMedical Co